Ardelyx (ARDX) News Today $5.80 -0.57 (-8.88%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Ardelyx Tops Estimates as Sales SurgeFebruary 20 at 1:58 PM | fool.comArdelyx reports Q4 EPS 2c, consensus 0cFebruary 20 at 9:15 AM | markets.businessinsider.comArdelyx reports Q4 EPS 2c, consensus 0cFebruary 20 at 9:15 AM | markets.businessinsider.comArdelyx, Inc. Reports Strong Financial Results for 2024 with $333.6 Million in Revenue and Reaffirms Peak Sales Projections for IBSRELA and XPHOZAHFebruary 20 at 8:00 AM | quiverquant.comArdelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 20 at 7:30 AM | globenewswire.comArdelyx (NASDAQ:ARDX) Trading Up 7.9% - Here's WhyArdelyx (NASDAQ:ARDX) Shares Up 7.9% - What's Next?February 19 at 10:56 PM | marketbeat.comArdelyx to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 19 at 8:01 AM | globenewswire.comArdelyx (ARDX) to Release Quarterly Earnings on ThursdayArdelyx (NASDAQ:ARDX) will be releasing earnings before the market opens on Thursday, February 20. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=661087)February 18 at 6:37 AM | marketbeat.comShort Interest in Ardelyx, Inc. (NASDAQ:ARDX) Increases By 12.7%Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 26,630,000 shares, an increase of 12.7% from the January 15th total of 23,620,000 shares. Based on an average daily trading volume, of 4,770,000 shares, the short-interest ratio is presently 5.6 days.February 15, 2025 | marketbeat.comArdelyx (ARDX) Expected to Announce Earnings on ThursdayArdelyx (NASDAQ:ARDX) will be releasing earnings before the market opens on Thursday, February 20. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=661087)February 13, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Quotes, Forecast and News SummaryFebruary 5, 2025 | benzinga.comArdelyx (NASDAQ:ARDX) Upgraded at Cantor FitzgeraldCantor Fitzgerald upgraded Ardelyx to a "strong-buy" rating in a research report on Thursday.February 1, 2025 | marketbeat.comMichael Raab Sells 41,666 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockFebruary 1, 2025 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 41,666 Shares of StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.36, for a total transaction of $223,329.76. Following the sale, the chief executive officer now directly owns 1,108,719 shares in the company, valued at $5,942,733.84. This trade represents a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.January 31, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating onJanuary 31, 2025 | marketbeat.comArdelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025January 30, 2025 | globenewswire.comPiper Sandler Releases a Hold Rating on Ardelyx (ARDX)January 28, 2025 | markets.businessinsider.comArdelyx (NASDAQ:ARDX) Price Target Raised to $8.00 at Piper SandlerPiper Sandler increased their target price on shares of Ardelyx from $7.00 to $8.00 and gave the company a "neutral" rating in a research note on Monday.January 28, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Expected to Rise, Piper Sandler Analyst SaysPiper Sandler increased their target price on Ardelyx from $7.00 to $8.00 and gave the company a "neutral" rating in a research report on Monday.January 27, 2025 | marketbeat.comWedbush Has Pessimistic Outlook of Ardelyx FY2024 EarningsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Wedbush lowered their FY2024 earnings estimates for shares of Ardelyx in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per shareJanuary 27, 2025 | marketbeat.comArdelyx Shares Rise as Chairman Mott Increases Stake in CompanyJanuary 23, 2025 | marketwatch.comArdelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying ActivityArdelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying ActivityJanuary 23, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Director David M. Mott Acquires 199,000 Shares of StockJanuary 23, 2025 | insidertrades.comArdelyx director David Mott buys $992,671 in company stockJanuary 22, 2025 | msn.comArdelyx director buys $992.7K in common stockJanuary 22, 2025 | markets.businessinsider.comArdelyx, Inc. (NASDAQ:ARDX) Director Buys $993,010.00 in StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David M. Mott bought 199,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was purchased at an average cost of $4.99 per share, for a total transaction of $993,010.00. Following the completion of the transaction, the director now directly owns 1,937,765 shares in the company, valued at approximately $9,669,447.35. This trade represents a 11.44 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.January 22, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Ardelyx FY2025 EarningsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Ardelyx in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biopharmaceutical company will earn ($0.13) per share for the year.January 22, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 164,480 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Hennion & Walsh Asset Management Inc. grew its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 25.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 808,392 shares of the biopharmJanuary 17, 2025 | marketbeat.comArdelyx’s Mixed Financial Outlook: Hold Rating Amid IBSRELA Growth and XPHOZAH ChallengesJanuary 16, 2025 | markets.businessinsider.comArdelyx (NASDAQ:ARDX) Earns Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating and set a $5.50 price target on shares of Ardelyx in a research note on Thursday.January 16, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Up 8.3% - Still a Buy?Ardelyx (NASDAQ:ARDX) Stock Price Up 8.3% - What's Next?January 15, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Down 3.7% - Time to Sell?Ardelyx (NASDAQ:ARDX) Trading Down 3.7% - What's Next?January 15, 2025 | marketbeat.comArdelyx’s Strategic Outlook and Financial Strength Indicate Strong Buy PotentialJanuary 15, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Ardelyx (ARDX)January 14, 2025 | markets.businessinsider.comArdelyx, Inc.: Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic PrioritiesJanuary 14, 2025 | finanznachrichten.deArdelyx's Ibsrela sales beat expectations, shares surgeJanuary 14, 2025 | in.investing.comArdelyx reports preliminary Q4 IBSRELA revenue $54MJanuary 14, 2025 | markets.businessinsider.comArdelyx (NASDAQ:ARDX) Stock Price Up 8.3% - What's Next?Ardelyx (NASDAQ:ARDX) Shares Up 8.3% - Here's WhyJanuary 13, 2025 | marketbeat.comArdelyx, Inc. Reports Strong Commercial Growth in 2024 with $319 Million in U.S. Net Product Sales and Reaffirms Revenue Expectations for IBSRELA and XPHOZAHJanuary 13, 2025 | quiverquant.comArdelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic PrioritiesJanuary 13, 2025 | globenewswire.comArdelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 SharesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $5.31, for a total transaction of $221,246.46. Following the completion of the transaction, the chief executive officer now owns 1,129,552 shares in the company, valued at $5,997,921.12. This represents a 3.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 10, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Up 5.8% - Should You Buy?Ardelyx (NASDAQ:ARDX) Stock Price Up 5.8% - Time to Buy?January 7, 2025 | marketbeat.comArdelyx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comArdelyx, Inc. (NASDAQ:ARDX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendationJanuary 6, 2025 | marketbeat.comPrincipal Financial Group Inc. Lowers Position in Ardelyx, Inc. (NASDAQ:ARDX)Principal Financial Group Inc. trimmed its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 71.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,439 shares of the biopharmaceuticJanuary 5, 2025 | marketbeat.comArdelyx price target lowered to $8 from $11 at JefferiesJanuary 2, 2025 | markets.businessinsider.comBeyond The Numbers: 4 Analysts Discuss Ardelyx StockJanuary 2, 2025 | benzinga.comJefferies Financial Group Issues Pessimistic Forecast for Ardelyx (NASDAQ:ARDX) Stock PriceJefferies Financial Group lowered their price objective on Ardelyx from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday.January 2, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Down 3.8% - Here's WhyArdelyx (NASDAQ:ARDX) Shares Down 3.8% - Should You Sell?December 31, 2024 | marketbeat.comWhy Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.com Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Media Mentions By Week ARDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDX News Sentiment▼0.370.54▲Average Medical News Sentiment ARDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDX Articles This Week▼58▲ARDX Articles Average Week Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYTK News Today VRNA News Today GRFS News Today TGTX News Today KRYS News Today SWTX News Today BHVN News Today RXRX News Today PTCT News Today OGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDX) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThe $3 Trillion AI GlitchForget the Border Crisis, China, and the Deep State. The biggest threat to Trump’s 2nd term could begin wit...Banyan Hill Publishing | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in FebruaryTrump’s World Liberty Bought $1M of THIS Coin Early investors could reap HUGE benefits…Crypto 101 Media | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDX Stock Alerts